Work

Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice

Year: 2013

Type: article

Abstract: We investigated the pre-clinical utility of carbon monoxide form of PEGylated hemoglobin (PEG-Hb also named SANGUINATE(™)) in myocardial infarction (MI) and in particular the response of diabetic tissues to superimposed ischemia/reperfusion injury. SANGUINATE(™) was evaluated in diabetic and normal mice subjected to 30 min of coronary artery ligation followed by either 48 h or 28 days of reperfusion. Our results demonstrate that SANGUINATE(™) was effective in reducing infarct size when administered either prior to left anterior descending coronary artery (LAD) occlusion or during reperfusion. This finding is an important step in exploring the efficacy of a pharmacoinvasive strategy using SANGUINATE(™) in patients with acute coronary syndromes.

Source: Artificial Cells Nanomedicine and Biotechnology

DOI: 10.3109/21691401.2012.762370

Authors: Radha Ananthakrishnan, Qing Li, Karen M. O’Shea, Nosirudeen Quadri, Lingjie Wang, Abraham Abuchowski, Ann Marie Schmidt, Ravichandran Ramasamy

Institutions: NYU Langone Health, Shanghai Jiao Tong University, Ruijin Hospital, Prolong Pharmaceuticals (United States)

Language: English

Topic: Cardiac Ischemia and Reperfusion

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2018700115

FWCI: 2.484

Cites: 42

Cited by: 42

Related to: 10